RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
1.110
-0.050 (-4.31%)
At close: Apr 3, 2025, 4:00 PM
1.130
+0.020 (1.80%)
Pre-market: Apr 4, 2025, 9:25 AM EDT

Company Description

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.

The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.

The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.

RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

RAPT Therapeutics, Inc.
RAPT Therapeutics logo
Country United States
Founded 2015
IPO Date Oct 31, 2019
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Brian Wong

Contact Details

Address:
561 Eccles Avenue
South San Francisco, California 94080
United States
Phone 650-489-9000
Website rapt.com

Stock Details

Ticker Symbol RAPT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.00
CIK Code 0001673772
CUSIP Number 75382E109
ISIN Number US75382E1091
Employer ID 47-3313701
SIC Code 2834

Key Executives

Name Position
Dr. Brian Russell Wong M.D., Ph.D. Chief Executive Officer, President and Director
Rodney K. B. Young Chief Financial Officer, Principal Accounting Officer and Secretary
Dr. William Ho M.D., Ph.D. Chief Medical Officer
Steve Young Ph.D. Vice President of Technology
Dr. Dirk G. Brockstedt Ph.D. Chief Scientific Officer
Michael Listgarten General Counsel
Gwen R. Carscadden Chief Human Resources Officer
Dr. Paul Kassner Ph.D. Senior Vice President of Biology
Jennifer Nicholson Senior Vice President of Regulatory Affairs and Quality Assurance
Dr. Nipun Davar MBA, Ph.D. Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 6, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 6, 2025 10-K Annual Report
Mar 6, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 SCHEDULE 13G/A Filing